Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Opportunities for nano-formulations in type 2 diabetes mellitus treatments

    Access Status
    Fulltext not available
    Authors
    Jeevanandam, J.
    Danquah, Michael
    Debnath, Sujan
    Meka, V.
    Chan, Yen S.
    Date
    2015
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Jeevanandam, J. and Danquah, M. and Debnath, S. and Meka, V. and Chan, Y. 2015. Opportunities for nano-formulations in type 2 diabetes mellitus treatments. Current Pharmaceutical Biotechnology. 16 (10): pp. 853-870.
    Source Title
    Current Pharmaceutical Biotechnology
    DOI
    10.2174/1389201016666150727120618
    ISSN
    1389-2010
    School
    Curtin Sarawak
    URI
    http://hdl.handle.net/20.500.11937/25593
    Collection
    • Curtin Research Publications
    Abstract

    Diabetes mellitus has been a threat to humans for many years. Amongst the different diabetes types, type 2 diabetes mellitus is the most common, and this is due to drastic changes in human lifestyle such as lack of exercise, stressful life and so on. There are a large number of conventional treatment methods available for type 2 diabetes mellitus. However, most of these methods are curative and are only applicable when the patient is highly symptomatic. Effective treatment strategies should be geared towards interfering with cellular and bio molecular mechanisms associated with the development and sustenance of the disease. In recent years, research into the medical potential of nanoparticles has been a major endeavor within the pharmaceutical industries. Nanoparticles display unique and tuneable biophysical characteristics which are determined by their shape and size. Nanoparticles have been used to manifest the properties of drugs, and as carriers for drug and vaccine delivery. Notwithstanding, there are further opportunities for nanoparticles to augment the treatment of a wide range of life threatening diseases that are yet to be explored. This review article seeks to highlight the application of potential nano-formulations in the treatment of type 2 diabetes mellitus. In addition, the activity of nanomedicine supplements in reversing insulin resistance is also discussed.

    Related items

    Showing items related by title, author, creator and subject.

    • Pharmaceutical care in diabetes mellitus
      Clifford, Rhonda (2004)
      People with diabetes mellitus are more likely to die from cardiovascular causes than those without diabetes, and modifiable risk factors, such as hyperglycaemia, dyslipidaemia and hypertension can be targeted in intervention ...
    • The Experience of Hypoglycaemia and Strategies Used for Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review
      Tan, S.; Chen, H.; Taylor, B.; Hegney, Desley (2011)
      Background: Hypoglycaemia, a common complication of diabetes drug therapy, has been reported to influence therapy adherence and the quality of life of people with diabetes mellitus. No systematic reviews on the experience ...
    • Teucrium polium: Potential Drug Source for Type 2 Diabetes Mellitus
      Albadr, Yaser ; Crowe, Andrew; Caccetta, Rima (2022)
      The prevalence of type 2 diabetes mellitus is rising globally and this disease is proposed to be the next pandemic after COVID-19. Although the cause of type 2 diabetes mellitus is unknown, it is believed to involve a ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.